Scarica l'app Stockscreener
1.67
18.44%
0.26
Tenaya Therapeutics Inc Borsa (TNYA) Ultime notizie
Tenaya Therapeutics (NASDAQ:TNYA) Earns Buy Rating from Chardan Capital - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) Earns “Buy” Rating from HC Wainwright - Defense World
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $17.33 Average PT from Brokerages - MarketBeat
Tenaya Therapeutics (NASDAQ: TNYA) Senior Vice President Chihiro Saito Resigns: 8-K Filing - Defense World
Tenaya Therapeutics stock backed by H.C. Wainwright on TN-401 safety and protein expression gains - Investing.com
Tenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from Chardan Capital - MarketBeat
Tenaya Therapeutics (NASDAQ:TNYA) Given "Buy" Rating at HC Wainwright - MarketBeat
Tenaya Stock Crashes as Cardio Gene Therapy Delivers Underwhelming Early-Stage Data - BioSpace
Contrasting Tenaya Therapeutics (NASDAQ:TNYA) and Vaxart (NASDAQ:VXRT) - Defense World
Tenaya Therapeutics stock hits 52-week low at $1.49 By Investing.com - Investing.com Canada
Tenaya stock in selloff on gene therapy data (TNYA:NASDAQ) - Seeking Alpha
Tenaya Therapeutics announces executive departure - Investing.com
Tenaya Therapeutics stock hits 52-week low at $1.49 - Investing.com
Tenaya Therapeutics Reports Promising TN-201 Trial Results - TipRanks
Tenaya Therapeutics’ Senior VP Resigns for New Opportunity - TipRanks
Tenaya reports positive early data on heart gene therapy - Investing.com
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy - GlobeNewswire
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 - The Manila Times
Tenaya Therapeutics to Unveil Groundbreaking Gene Therapy Data for Heart Disease Treatment - StockTitan
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 - GlobeNewswire
Fmr LLC Raises Stock Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics' SWOT analysis: gene therapy stock faces pivotal catalysts - Investing.com
Jacobs Levy Equity Management Inc. Buys 226,466 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - MarketBeat
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stake Decreased by RA Capital Management L.P. - MarketBeat
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest Update - MarketBeat
Around the Helix: Cell and Gene Therapy Company Updates – November 27, 2024 - CGTLive™
First Patient Dosed in RIDGE-1 Trial for Tenaya’s ARV Cardiomyopathy Gene Therapy TN-401 - CGTLive™
Tenaya shares retain Buy rating, price target on trial update - Investing.com
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase - GlobeNewswire
Tenaya Therapeutics Launches First-Ever PKP2-ARVC Gene Therapy Trial, Doses Initial Patient | TNYA Stock News - StockTitan
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $14.75 Average Target Price from Brokerages - MarketBeat
Tenaya Therapeutics Reports Q3 2024 Progress and Financial Results - TipRanks
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Tenaya Therapeutics Issues Stock Options to New Employees at $1.97 Per Share | TNYA Stock News - StockTitan
Tenaya Therapeutics SVP sells $4,786 in stock By Investing.com - Investing.com UK
Tenaya Therapeutics SVP sells $4,786 in stock - Investing.com
RA Capital Management's Strategic Acquisition in Tenaya Therapeu - GuruFocus.com
Research Analysts Offer Predictions for TNYA FY2024 Earnings - MarketBeat
Leerink Partnrs Issues Optimistic Estimate for TNYA Earnings - MarketBeat
William Blair Brokers Increase Earnings Estimates for TNYA - MarketBeat
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) large institutional owners must be happy as stock continues to impress, up 42% over the past week - Simply Wall St
Tenaya Therapeutics (NASDAQ:TNYA) Price Target Lowered to $18.00 at Chardan Capital - MarketBeat
Latham Group, Inc. to Participate in the Baird 2024 Global Industrial Conference - The Manila Times
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
abrdn plc Invests $1.06 Million in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - MarketBeat
BeyondSpring (BYSI) Stock Drops Amid Biotech Sector Volatility - GuruFocus.com
Beam Therapeutics (BEAM) Stock Surges with Strong Trading Volume - GuruFocus.com
Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation - Yahoo Finance
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):